Budget Impact Analysis of Lanadelumab Versus C1 Inhibitor for Hereditary Angioedema Long Term Prophylaxis: A Brazilian Private Sector Perspective
Author(s)
Tatiane Ribeiro, MSc, Lucas Azevedo, Market Access Intern, Juliana Guedes, M.D, Bruno B. Rosa, MSc., Daniela Morais, MBA, PharmD.
Takeda, São Paulo, Brazil.
Takeda, São Paulo, Brazil.
OBJECTIVES: Hereditary angioedema (HAE) is an ultra-rare condition that can cause severe and recurrent attacks. Long-term prophylaxis with Lanadelumab offers a new therapeutic option, more effective compared to currently available C1 esterase inhibitors (C1-INH). The objective of this study is to compare the budget impact of incorporating Lanadelumab versus maintaining current treatments with C1-INH IV and SC for the prophylaxis of HAE from the perspective of Brazilian supplementary health
METHODS: A 5-year budget impact analysis was conducted. The model considered two scenarios: the current one with C1-INH IV and SC treatments, and the future one with Lanadelumab. The eligible population was assessed based on epidemiological data, estimating 113 patients in the first year and 128 in the fifth year. Diffusion rates of 40% in the first year for Lanadelumab, increasing to 80% in the fifth year, were adopted. Direct medical costs, including prophylaxis, on-demand drug treatment and administration costs, attack management based on severity, and adverse event management were included
RESULTS: The analysis showed that incorporating Lanadelumab resulted in savings of R$ 281,522,532 over five years. This saving is due to reduced long-term treatment costs, considering the significant decrease in HAE attacks compared to C1-INH IV and lower treatment costs versus C1-INH SC. Even with the initial cost increase in the first year due to the new treatment, long-term cost avoidance outweighed these increments. A univariate sensitivity analysis identified the most influential variables: treatment costs with the drugs included in the budget impact analysis and patient weight
CONCLUSIONS: The budget impact analysis suggests that the incorporation of Lanadelumab for the prophylaxis of HAE can generate substantial savings for the Brazilian supplementary health system
METHODS: A 5-year budget impact analysis was conducted. The model considered two scenarios: the current one with C1-INH IV and SC treatments, and the future one with Lanadelumab. The eligible population was assessed based on epidemiological data, estimating 113 patients in the first year and 128 in the fifth year. Diffusion rates of 40% in the first year for Lanadelumab, increasing to 80% in the fifth year, were adopted. Direct medical costs, including prophylaxis, on-demand drug treatment and administration costs, attack management based on severity, and adverse event management were included
RESULTS: The analysis showed that incorporating Lanadelumab resulted in savings of R$ 281,522,532 over five years. This saving is due to reduced long-term treatment costs, considering the significant decrease in HAE attacks compared to C1-INH IV and lower treatment costs versus C1-INH SC. Even with the initial cost increase in the first year due to the new treatment, long-term cost avoidance outweighed these increments. A univariate sensitivity analysis identified the most influential variables: treatment costs with the drugs included in the budget impact analysis and patient weight
CONCLUSIONS: The budget impact analysis suggests that the incorporation of Lanadelumab for the prophylaxis of HAE can generate substantial savings for the Brazilian supplementary health system
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE438
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
SDC: Rare & Orphan Diseases